New drug for arthritis and lupus enters first human safety tests
NCT ID NCT06917742
First seen Apr 01, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This early-stage study tests a new drug called CPTX2309 in healthy people and those with moderate to severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The main goal is to check if the drug is safe and tolerable. About 64 adults will take part, receiving the drug through an IV. This is a first-in-human trial, so it focuses on safety rather than effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Brisbane
RECRUITINGHerston, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.